Eli Lilly (NYSE:LLY) shares have been hitting new highs, boosted by a recent strong earnings report and another raised ...

Even by dramatically lowering the prices of some of its medications, the drug giant is still outpacing its rivals and nearing ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly and Co.’s stock hit an all-time high and almost reached $1,000 per share on Tuesday in the wake of several ...

While the pharma giant Eli Lilly has lagged behind the broader market over the past year, it has outpaced the health care space, and analysts remain strongly bullish on the stock’s prospects.

Eli Lilly’s stock reached an all-time high of $1022.62 USD, marking a significant milestone for the pharmaceutical giant. According to InvestingPro data, the company’s RSI suggests the stock is in ...

Shares of Eli Lilly & Co. are being fueled by enthusiasm over the company's recent deal with the Trump administration. As Jaimy Lee reports, this enthusiasm is based in part on the addition of ...

Eli Lilly shares are rising Monday after Leerink Partners upgraded the stock to Outperform and raised its price target to ...

Eli Lilly shares are trading higher on Monday. The pharmaceutical giant announced a significant European manufacturing expansion.

Eli Lilly has a leading position in a hot new drug category, but there's one notable problem to consider.

Now, let’s talk about the real contenders, okay. Let’s start with Eli Lilly, one I always said was going to get to trillion dollars, but it’s really stumbled here. It’s in fourth.

Novo Nordisk A/S & Eli Lilly and Company cut prices for top diabetes drugs, boosting accessibility and potential revenue.